Expert Financial Analysis and Reporting

Executive Summary I have tried to make this report as short and readable as possible so that in many cases I provide links to a previous article I have written or other pertinent data, rather than recreating the information in this report. So, you will find lots of links. The intent is to give the […]

Introduction Let me ask you a question? If Adam Feuerstein is trying to convince you that DCVax-L has no chance of being effective in glioblastoma multiforme (GBM), wouldn’t you expect him to have a good understanding of the biological basis for the product, its mechanism of action and how it is manufactured (especially the case […]

F-stein Challenges Members of the Oncology Community Who Treat Glioblastoma Multiforme Adam Feuerstein has thrown down the gauntlet in alleging that over 40 practicing oncologists who participated in the phase 3 trial of DCVax-L have misrepresented the findings. The results of the phase 3 trial were presented at the New York Academy of Science on […]

Introduction I am really outraged. The long awaited phase 3 results for DCVax-L in newly diagnosed and recurrent glioblastoma multiforme were a stunning success. The data was peer reviewed and presented at the prestigious New York Academy of Sciences on May 10, 2022. I discuss the data at length in this report and I am […]

The media focus on corrupt hedge fund short selling has not surprisingly turned to bloggers who are closely associated with short selling. The first casualty has been Andrew Left of Citron Research who was leading the charge on shorting GameStop and got hammered on his short position. The Wall Street Journal reports  that his firm […]

Introduction Adam Feuerstein just published a blog that attacks the results and conclusions drawn from the paper summarizing results from the 51 patient information arm of the DCVax-L phase 3 trial. This marks the 22nd consecutive negative blog by Feuerstein on Northwest. I am growing tired of rebutting his articles, but as long as he […]

Perspective I think that all investors in Northwest Biotherapeutics (NWBO) would concur that Adam Feuerstein has a vendetta against NWBO and its management. He has written 19 negative blogs (or is it 20) on the company just since March 2014. Since September of 2013, NASDAQ reports that the short interest on Northwest has increased from […]

  The Data Monitoring Committee (DMC) is charged with monitoring the safety and efficacy results of clinical trial. The committee and its chairman are totally independent of NWBO. The Chairman of the DMC says there has been no interim analysis for efficacy of the phase 3 trial. Feuerstein alleged that efficacy results were negative and […]

Citizens for Responsibility and Ethics in Washington (CREW) have gone after Adam Feuerstein of The Street.com. They have accused him of taking part in a stock manipulation scheme in regard to Northwest Biotherapeutics and other biotechnology companies. I went to their website to get an idea of who they are. They refer to some of […]

Adam Feuerstein has just  launched its 16th negative blog on Northwest Biotherapeutics since the beginning of March and this has caused the stock to decline about $0.88 in early trading. The link to his blog is http://www.thestreet.com/story/12749366/1/prestigious-cancer-hospital-rebukes-northwest-bio-for-inappropriate-data-disclosures.html  and the title of the blog is “Prestigious Cancer Hospital Rebukes Northwest Bio for ‘Inappropriate’ Data Disclosures” Here […]